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LVM indexed by BSA** Height* Height2.7 LBM** 
Male 73 _+ 16 g/m 2 89 ± 21 g/m 33 ± 7 g/m 2"7 2.68 ± 0.52 g/kg 
Female 64± 13 g/m 2 75 ± 13 g/m 33 ± 6 g/m2.7 3.07 ± 0.60 g/kg 
1108-96 Arterial Stiffness and Left Ventricular Geometry and 
Function in Hypertensive Patients With 
Electrocardiographic Left Ventricular Hypertrophy: The 
LIFE Study 
Vittorio Palmieri, Jonathan N. Bella, Mary J. Roman, Eva Gerdts, Vasilios 
Papademetriou, Kristian Wachtell, Markku S. Nieminen, Bj6rn Dahl6f, Richard B. 
Devereux, WeN Medical College of Come//Universi~ New York, New York. 
Background: Arterial stiffness can be assessed by the ratio pulse pressure (PP) over 
echocerdiographic stroke volume (SV). We evaluated relations of arterial stiffness to left 
ventricular (LV) geometry and function in hypertensive patients with electrocardiographic 
(ECG) LV hypertrophy (H). 
Methods: Of participants in the echo-substudy of the Losartan Intervention For Endpoint 
(LIFE) reduction in hypertension study, selected to have ECG-LVH by Cornell voltage-dura- 
tion product or Sokolow-Lyon voltage criteria, no heart failure or severe aortic stenosia, we 
identified 858 subjects (88%, 66+-7 yrs/old) with PP/SV available. The study sample was 
divided in tertiles of PP/SV (cutpoints: 0.86 and 1.11 mm Hg/ml). M-mode and Doppler SV 
were averaged. 
Results: With higher PP/SV, age, proportions of women and diabetics, and systolic blood 
pressure (BP) were higher (all p<0.01); diastolic BP, body height and weight, and SV were 
lower (all p<0.01). Mean BP, totaVHDL cholesterol, urinary albumin/creatinine and propor- 
tion of wall motion abnormalities were similar in tertiles of PP/SV. After adjusting for age, 
gender and body surface area, LV mass and LV intemal diameter were lower while relative 
wall thickness (RWT=LV concentricity) was higher with higher PP/SV (all p<0.01); ejection 
fraction was similar across tertiles (p>0.5) while stress-corrected midwall shortening 
(scMWS) was lower with higher PP/SV (p<0.01). After adjustment for age and gender, LV 
filling parameters and heart rate were similar in tertiles of PP/SV (all p>O.1). In multivariate 
models, independent correlates of PP/SV were older age, lower body weight, female-gen- 
der end diabetes (R=0".48, p<0.00t); higher RWT was related to higher PP/SV independent 
of age, gender, and mean BP (R=0.30, p<0.001); higher LV mass was independently pre- 
dicted by higher SV, male-gender, higher body weight, older age and higher mean BP, but 
not PP (R=0.64, p<0.001); PP/SV was not related to scMWS independent of RWT. 
Conclusions: In elderly hypertensives with ECG-LVH, higher arterial stiffness is related to 
concentric LV geometry, which may offset afterload and preserve LV chamber function, but 
is associated with impaired myocardial function. 
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825FO-2 Add i t ion  of  StaUn Attenuates the Increase in C-React ive 
Protein During Estrogen Replacement Therapy in 
Postmenopeuee l  Women 
Kwano K. Koh, Gyorgy Cseko, William Schenke, Richard O. Cannon, III, NHLBI, 
Bethesda, Maryland. 
Background: Randomized clinical trials have shown that HMG-CoA reductase inhibitor 
(statin) therapy reduces cardiovascular risk, the mechanism of which may include dimin- 
ished arterial inflammation as evidenced by reduction in levels of C-reactive protein (CRP) 
in serum, Because estrogen replacement therapy increases CRP in postmenopausal 
women, which coutd have pro-inflammatory consequences and compromise any benefit to 
cardiovascular risk, we determined whether the addition of statin might modify the estro- 
genic effect on CRP. Methods: in a double blind, 3-period crossover study, we randomly 
assigned 28 healthy postmenopausel women to conjugated equine estrogens (CEE) 0.625 
rag, simvastatin 10 rag, and their combination daily for 6 weeks, with each treatment period 
separated by 6 weeks off drugs. CRP was measured by high sensitivity immunomethc 
assay (sensitivity 0.01mg/dL) before and after 6 weeks of each treatment. Results: CEE 
increased CRP from 0.37 ± 0.06 to 0.65 ± 0.13 mg/dL, simvastatin decreased CRP from 
0.37 ± 0.06 to 0.33 ± 0.05 mg/dL, and the therapies combined increased CRP from 0.38 ± 
0.08 to 0.48 ± 0.08 mg/dL (all P<0.02 vs. respective baseline values), with significant differ- 
ences in changes in CRP levels among these therapies (P<O.05 by ANOVA). Post-hoc 
testing showed that the 29 ± 8 % increase in CRP on the combination of CEE with simvas- 
tatin was significantly less than the 89 ± 32 % increase in CRP on CEE alone (P<0.0t). 
The effect of combination therapy on CRP did not correlate with baseline CRP, or with 
baseline or traatment-inducod changes in levels of LDL cholesterol, HDL cholesterol, inter- 
leukin-6, or brachlal artery flow-mediated ilation as a measure of nitric oxide bioactivity (all 
r<0.32). Conclusion: The combination of statin with estrogen therapy may attenuate the 
potential preinflammatory effect of estrogen administration to postmenopausat women, and 
maximize any benefit of hormone replacement herapy to cardiovascular isk. 
2:30 p.m. 
825FO-3 The Dif ferent ia l  Effects of Hormone Replacement 
Therapy and Selective Estrogen Receptor Modulator on 
Endothelial Function Seem Related to  an Effect on 
Plasma Asymmetric Dimethylarglnine, an Inh ib i tor  o f  
Nitr ic Ox ide  Syntheee  
Giuseppe Mercuro, Massimo Fini, Cristiana Vitale, Otavio Gebara, Sandra Zoncu, 
Mauricio Wajngarten, Antonello Silvestri, Paola Rossini, Josh Antonio E Ramires, 
Giuseose M. Rosano, San Raffae/e Hospital, Rome,/ta/y, University of Cag/ia~ 
Cag/ia~ Italy. 
Background: Hormone replacement therapy (HRT) improves endothelial function in 
postmenopausal women. Although in vitro animal studies suggest that the selective 
estrogen receptor modulator, raloxifene (R), improves endothelial function, its effect in 
women has yielded conflicting results. One mechanism by which HRT may reverse 
endothelial dysfunction and increase NO bioavaitability is by lowering asymmetric dime- 
thylarginine (ADMA), an endogenous inhibitor of nitric oxide (NO) synthase. The aim of 
this study was to evaluate endothelial function and plasma ADMA with HRT or R. 
Methods: Brachlal artery diameter, endothelium-dependent flow-mediated vasodilation 
(FMD) of the brachial artery, and plasma levels of nitrite, nitrate, endothelin-1 and ADMA 
were measured in 20 bostmenopausel women with increased cardiovascular risk, treated 
with either HRT (0.625 conjugated equine estrogens and 2.5 mg medroxyprogesterone 
acetate) or R (60 rag) for 4 weeks in a double-blind, single cross-over study. 
Results: Baseline brechial artery diameters remained unchanged after each treatment 
phase. FMD significantly improved with HRT but not with R. ADMA significantly 
decreased with HRT, while a trend towards increased plasma ADMA levels was noted 
with R. 
Conclusions: HRT improves endothelial function in postmenopausel women at risk of 
cardiovascular disease, which may be due, at least in part, to a reduction in ADMA. In 
contrast, R seems to increase plasma ADMA, which may negatively affect endothelial 
function. 
Baseline HRT R 
FMD (%) 7.4_+.0.5 12.4+_0.6"* 6.1+_2.0 
ADMA 0.76+0.51 0.68_+0.63** 0.80+_0.65 
Nitrite+nitrate (Nox) 41.1_+10.3 47.3+-8.4* 38.8+-6.8 
Endothelin-1 (pg/ml) 3.2+_0.6 2.8_+0.6* 3.2+0.7 
*=p<0.05; **=p<0.01, compared to baseline 
2:45 p.m. 
825FO-4 Hormone Replacement Therapy and Risk of Myocardial 
Infarction in Women With Diabetes 
Aooor S. Gami, R. Scott Wright, Sharonne E. Hayes, Stephen L. Kopecky, Mayo Clinic, 
Rochester, Minnesota. 
Background: The effect of hormone replacement herapy (HRT) on coronary heart disease 
(CHD) in postmenopausal women is controversial Women with diabetes are at markedly 
increased risk of CHD, yet data on HRT in this population is scarce. The purpose of this 
study is to describe the effect of HRT on risk of MI in postmenopausel women with diabetes. 
Methods: We conducted a case-control study in which case subjects (n = 99) were consec- 
utive postmenopausal women with diabetes admitted to our institution from 1998 to 2000 
with a principal diagnosis of ML Control subjects (n = 306), matched in a 3:1 ratio by age 
and admission year, were postmenopausal women with diabetes admitted with principal 
diagnoses other than MI. Medical records were reviewed for demographics, medical history 
including diabetes complications, CHD risk factors, laboratory data, and current medica- 
tions. Differences between case and control groups were assessed by the two-sample T- 
test for continuous variables and the chi-square test for dichotomous variables. The odds 
ratio, adjusted for group differences by logistic regression models, was used to estimate the 
relative risk of incident MI for HRT users. 
Results: Case and control subjects were of similar age (73 years), height (157 cm), and 
weight (77 kg). Case and control groups had similar frequencies of hypertension (73°/°) and 
active cigarette use (8%). Frequencies of use of insulin (53%), oral hypoglycemic agents 
(36%), aspirin (46%), and statins (22%) were similar. Frequencies of diabetic retinopathy 
(19%), neuropethy (21%), and nephropathy (32%) were similar. Average levels of hemoglo- 
bin Alc (8.6%) and creatinine (1.7 mg/dt) were similar. More case subjects had previous MI 
(29% vs. 17°, p = 0.01) and hypercholesterolemia (52% vs. 39%, p = 0.02). Current users 
of estrogen (with or without progesterone) comprised 16% of case and 18% of control sub- 
jects. The relative risk of incident MI for current HRT users was 0.92 (95% CI 0.44 - 1.94). 
assessing body composition and LVM, we examined the gender difference of LVM adjusted 
for LBM in older persons with mild hypertension. 
Method: Fifty-two subjects (22 men and 30 women) with untreated mild hypertension, aged 
55 to 75 years, and otherwise healthy, were examined. Resting BP was obtained at 4 or 5 
visits at least 1 week apart and averaged. Body composition was assessed using dual 
energy X-ray absorptiometry. LVM was determined from MRI and was indexed by BSA, 
height, height 2'7 and LBM. 
Results: There were no gender differences in age, SBP and BMI. Men had higher mean BP, 
uniodexed LVM, and LBM than women. Fat mass and percent body fat were higher in 
women compared to men. Unlike the LVM indexed by other measures, LVM indexed by LBM 
was greater in women than men, as shown in table. In a multiple regression model, gender 
was a predictor of LVM after adjustment for LBM, mean BP, percent body fat and LBM - gen- 
der interaction (adjusted means, female vs. male, 135 ± 8 g vs. 109 ± 12 g, p < 0.05) 
Conclusion: in this population of older persons with mild hypertension, women had a higher 
LVM relative to their lean body size, suggesting that women may be more susceptible to LVH 
than men. 
Table * p < 0.01, ** p < 0.05, male vs. female 
